(R)-3-N-叔丁氧羰基氨基丁胺 | 170367-69-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-3-N-叔丁氧羰基氨基丁胺
• 中文别名: (R)-3-N-叔丁氧羰基丁烷-1,3-二胺；(R)-3-boc-氨基丁胺
• 英文名称: (R)-N³-(tert-butyloxycarbonyl)-1,3-diaminobutane
• 英文别名: (R)-3-Boc-amino-butylamine；tert-butyl N-[(2R)-4-aminobutan-2-yl]carbamate
• CAS: 170367-69-8
• 化学式: C₉H₂₀N₂O₂
• 分子量: 188.27
• InChiKey: JOFFSNZHLGGAJC-SSDOTTSWSA-N

物化性质

• 沸点：
  282.6±23.0 °C(Predicted)
• 密度：
  0.972±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (R)-3-Boc-amino-butylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (R)-3-Boc-amino-butylamine
CAS number: 170367-69-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H20N2O2
Molecular weight: 188.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-3-N-叔丁氧羰基氨基丁胺 在 镍 sodium tetrahydroborate 、 3 A molecular sieve 、 氨 、 氢气 、 sodium carbonate 、 potassium iodide 作用下， 以 乙醚 、 乙醇 、 正丁醇 为溶剂， 10.0~20.0 ℃ 、600.0 kPa 条件下， 反应 58.0h， 生成 3-[(4-aminobutyl)(phenylmethyl)amino-1(R)-methylpropyl]carbamic acid, 1,1-dimethylethyl ester
  参考文献：
  名称：

  Structure−Immunosuppressive Activity Relationships of New Analogues of 15-Deoxyspergualin. 2. Structural Modifications of the Spermidine Moiety

  摘要：

  A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Various substitutions of the spermidine "D" region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. Various positions of methylation were first investigated leading to the discovery of the monomethylated malonic derivative 56h in which the pro-R hydrogen of the methylene a to the primary amine of the spermidine moiety has been replaced by a methyl group. Synthesis of the similarly methylated analogue of the previously reported glycolic derivative LF 08-0299 afforded 60e which demonstrated a powerful activity at a dose as low as 0.3 mg/kg in the GVHD model and was much more potent than DSG in the demanding heart allotransplantation model in rats. The improvement of in vivo activity was supposed to be related to an increase of the metabolic stability of the methylated analogues compared to the parent molecules. Due to its very low active dose, compatible with a subcutaneous administration in humans, and its favorable pharmacological and toxicological profile, 60e was selected as a candidate for clinical evaluation.

  DOI：

  10.1021/jm991043x
• 作为产物：
  描述：

  (2R)-2-[(tert-butoxycarbonyl)amino]propyl methanesulfonate 在 Raney-Ni 氨 、 氢气 作用下， 以 乙醇 、 水 、 二甲基亚砜 为溶剂， 70.0 ℃ 、379.22 kPa 条件下， 反应 2.0h， 生成 (R)-3-N-叔丁氧羰基氨基丁胺
  参考文献：
  名称：

  WO2006/116764

  摘要：

  公开号：

文献信息

• Practical and scalable synthesis of orthogonally protected-2-substituted chiral piperazines
  作者：Srinivas Chamakuri、Manuj M. Shah、David C. H. Yang、Conrad Santini、Damian W. Young

  DOI：10.1039/d0ob01713b

  日期：——

  orthogonally protected, enantiomerically pure 2-substituted piperazines is described. Starting from α-amino acids, within four steps chiral 2-substituted piperazines are obtained. The key transformation involves an aza-Michael addition between an orthogonally bis-protected chiral 1,2-diamine and the in situ generated vinyl diphenyl sulfonium salt derived from 2-bromoethyl-diphenylsulfonium triflate

  描述了一种正交保护的、对映体纯的 2-取代哌嗪的合成路线。从 α-氨基酸开始，在四步内获得手性 2-取代哌嗪。关键的转化涉及正交双保护手性 1,2-二胺和原位生成的由 2-溴乙基-二苯基锍三氟甲磺酸盐衍生的乙烯基二苯基锍盐之间的氮杂迈克尔加成。进行了使用不同保护基团的进一步验证以及多克规模的合成。该方法还应用于手性1,4-二氮杂环己烷和1,4-二氮杂环己烷的构建。此外，该方法用于手性米氮平的正式合成。
• [EN] TRIAZACYCLODODECANSULFONAMIDE ("TCD")-BASED PROTEIN SECRETION INHIBITORS<br/>[FR] INHIBITEURS DE SÉCRÉTION DE PROTÉINE À BASE DE TRIAZACYCLODODÉCANSULFONAMIDE ("TCD")
  申请人：KEZAR LIFE SCIENCES

  公开号：WO2019178510A1

  公开（公告）日：2019-09-19

  Provided herein are triazacyclododecansulfonamide ("TCD")-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

  本文提供了基于三氮杂环十二烷磺酰胺（"TCD"）的蛋白质分泌抑制剂，例如Sec61的抑制剂，其制备方法，相关的药物组合物，以及使用它们的方法。例如，本文提供了符合Formula（I）的化合物及其药用盐和包括它们的组合物。本文披露的化合物可以用于治疗炎症和/或癌症等疾病。
• Synthesis of novel optical isomers of α-methylpolyamines
  作者：Nikolay A. Grigorenko、Alex R. Khomutov、Tuomo A. Keinänen、Aki Järvinen、Leena Alhonen、Juhani Jänne、Jouko Vepsäläinen

  DOI：10.1016/j.tet.2006.12.065

  日期：2007.3

  Earlier unknown (R)- and (S)-α-methylspermidine, (R)- and (S)-α-methylspermine, (R,R)-, (S,S)-, and (R,S)-α,ω-dimethylspermine were synthesized in gram scale from readily available (R)- and (S)-2-aminopropanols in high overall yields.

  早期未知的（R）-和（S）-α-甲基亚精胺，（R）-和（S）-α-甲基亚精胺，（R，R）-，（S，S）-和（R，S）-α从容易获得的（R）-和（S）-2-氨基丙醇以克级合成γ-ω-二甲基精胺，总收率高。
• [EN] HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS<br/>[FR] COMPOSÉS PYRIDYLE À SUBSTITUTION HÉTÉROARYLE UTILES EN TANT QUE MODULATEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014074675A1

  公开（公告）日：2014-05-15

  Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

  具有以下式(I)或其立体异构体或药用可接受盐的化合物，在该式中R2是单环杂芳基，R1、R3、R4、R5和R6如本文所定义，可用作激酶调节剂，包括IRAK-4抑制剂。
• [EN] PYRROLOPYRAZINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLOPYRAZINE KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013030138A1

  公开（公告）日：2013-03-07

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及式I的新型吡咯并吡嗪衍生物的使用，其中变量如本文所述定义，其抑制JAK和SYK，并可用于治疗自身免疫和炎症性疾病。